https://scholars.lib.ntu.edu.tw/handle/123456789/627197
標題: | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | 作者: | ANN-LII CHENG Qin, Shukui Ikeda, Masafumi Galle, Peter R Ducreux, Michel Kim, Tae-You Lim, Ho Yeong Kudo, Masatoshi Breder, Valeriy Merle, Philippe Kaseb, Ahmed O Li, Daneng Verret, Wendy Ma, Ning Nicholas, Alan Wang, Yifan Li, Lindong Zhu, Andrew X Finn, Richard S |
關鍵字: | PD-L1 inhibitor; advanced hepatocellular carcinoma; combination treatment; first-line systemic treatment; overall survival; survival benefit | 公開日期: | 四月-2022 | 出版社: | ELSEVIER | 卷: | 76 | 期: | 4 | 起(迄)頁: | 862 | 來源出版物: | Journal of hepatology | 摘要: | IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared with sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of follow-up). We present updated data after 12 months of additional follow-up. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627197 | ISSN: | 0168-8278 | DOI: | 10.1016/j.jhep.2021.11.030 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。